AMEX Rules Require Bio-Rad to Replace Deceased Director in 90 Days | GenomeWeb
NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said it is not in compliance with American Stock Exchange listing requirements after the death of a director last week left the company without the required number of audit committee members.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.